Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Cabaletta Bio ( (CABA) ).
On April 20, 2026, Cabaletta Bio posted an updated corporate presentation outlining progress and plans for rese-cel, its CD19-CAR T cell therapy for autoimmune diseases, on the Investors & Media section of its website. The presentation highlights a pivotal myositis study now enrolling, the generation of clinical data in 2026 from pemphigus vulgaris and systemic lupus erythematosus cohorts treated without preconditioning, and the advancement of automated manufacturing intended to support broader, scalable clinical and future commercial use of rese-cel.
The most recent analyst rating on (CABA) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Cabaletta Bio stock, see the CABA Stock Forecast page.
Spark’s Take on CABA Stock
According to Spark, TipRanks’ AI Analyst, CABA is a Neutral.
The score is held back primarily by weak financial performance (no revenue, widening losses, and heavy ongoing cash burn), partially offset by positive corporate progress and financing/runway visibility. Technicals are mixed and valuation metrics are not supportive due to negative earnings and no dividend.
To see Spark’s full report on CABA stock, click here.
More about Cabaletta Bio
Cabaletta Bio, Inc. is a biotechnology company focused on developing targeted cellular therapies for patients with autoimmune diseases. Its lead program centers on rese-cel, a CD19-directed CAR T cell therapy candidate aimed at delivering potentially curative, drug‑free, durable responses in a range of autoimmune indications.
Average Trading Volume: 3,069,688
Technical Sentiment Signal: Hold
Current Market Cap: $378.5M
See more data about CABA stock on TipRanks’ Stock Analysis page.